Stockreport

In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly [Yahoo! Finance]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF Danish biopharma powerhouse Novo Nordisk is taking another bold move in the obesity market, this time licensing a new type of GLP-1 that could directly compete with a c [Read more]